Beta Drugs Ltd.

As of June 30, 2026, Beta Drugs Ltd. carries a market capitalization of 24.22B, placing it among publicly traded companies globally. Its enterprise value stands at 24.22B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Beta Drugs Ltd.'s next confirmed earnings release is scheduled for February 15, 2027.

As of June 30, 2026, Beta Drugs Ltd. has 11.09M shares outstanding.

As of June 30, 2026, Beta Drugs Ltd. trades at a trailing price-to-earnings ratio of 91.54.

As of June 30, 2026, Beta Drugs Ltd. trades at an EV/EBITDA multiple of 53.77 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 11.03 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 67.46 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 24.22B versus a market cap of 24.22B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 4.82M in revenue per employee across its workforce of 455.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Beta Drugs Ltd. recorded 83.39M in income tax expense. That works out to an effective tax rate of 24.62, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 338.73M, leaving 248.51M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Beta Drugs Ltd.'s stock has gained approximately 4.21% over the past 52 weeks. The 50-day moving average sits at 2,107.69, while the 200-day moving average is 1,713.21.

Over the twelve months ended June 30, 2026, Beta Drugs Ltd. generated 2.20B in revenue and converted that into 248.51M in net income, yielding earnings per share of 24.52. EBITDA reached 450.46M, while operating income came in at 359.03M.

Over the twelve months ended June 30, 2026, Beta Drugs Ltd. posted a gross margin of 58.72, reflecting its pricing power and cost economics. The operating margin of 16.36 and net profit margin of 11.32 provide insight into operational efficiency.

Beta Drugs Ltd.'s most recent stock split took place on March 26, 2025 with a 20:21 split ratio.